Woodson B Tucker, Steward David L, Weaver Edward M, Javaheri Shahrokh
Department of Otoraryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Otolaryngol Head Neck Surg. 2003 Jun;128(6):848-61. doi: 10.1016/S0194-59980300461-3.
The study goal was to determine the effectiveness of (1) multilevel temperature-controlled radiofrequency tissue ablation (TCRFTA) or (2) continuous positive airway pressure (CPAP) for the treatment of mild to moderate obstructive sleep apnea syndrome (OSAS).
We conducted a randomized, placebo-controlled, 2-site trial, comparing TCRFTA (n = 30) and CPAP (n = 30) with sham-placebo (n = 30) using intention-to-treat analysis.
Compared with pretreatment baseline, TCRFTA improved reaction time, OSAS-specific quality of life (QOL), and subjective sleepiness (all P < 0.05). Compared with sham-placebo, TCRFTA improved QOL, airway volume, apnea index, and respiratory arousal index (all P < 0.05). TCRFTA side effects and complications were mild, temporary, and similar to sham-placebo. CPAP improved QOL and sleepiness compared with baseline and QOL when compared with sham-placebo (all P < 0.05). Significant differences were not seen between TCRFTA and CPAP outcomes.
TCRFTA and CPAP each improve QOL for mild-moderate OSAS patients. TCRFTA improvements may result from changes in airway volume, apnea index, and respiratory arousal index.
本研究的目标是确定(1)多级温度控制射频组织消融术(TCRFTA)或(2)持续气道正压通气(CPAP)治疗轻度至中度阻塞性睡眠呼吸暂停综合征(OSAS)的有效性。
我们进行了一项随机、安慰剂对照、双中心试验,采用意向性分析,比较TCRFTA组(n = 30)、CPAP组(n = 30)与假安慰剂组(n = 30)。
与治疗前基线相比,TCRFTA改善了反应时间、OSAS特异性生活质量(QOL)和主观嗜睡程度(均P < 0.05)。与假安慰剂相比,TCRFTA改善了生活质量、气道容积、呼吸暂停指数和呼吸唤醒指数(均P < 0.05)。TCRFTA的副作用和并发症轻微、短暂,且与假安慰剂相似。与基线相比,CPAP改善了生活质量和嗜睡程度,与假安慰剂相比也改善了生活质量(均P < 0.05)。TCRFTA和CPAP的治疗效果未见显著差异。
TCRFTA和CPAP均可改善轻中度OSAS患者的生活质量。TCRFTA的改善可能源于气道容积、呼吸暂停指数和呼吸唤醒指数的变化。